302 related articles for article (PubMed ID: 23598488)
21. Pre-erythrocytic malaria vaccines: towards greater efficacy.
Hill AV
Nat Rev Immunol; 2006 Jan; 6(1):21-32. PubMed ID: 16493425
[TBL] [Abstract][Full Text] [Related]
22. [New hope for malaria vaccine].
Holzgrabe U
Pharm Unserer Zeit; 2009; 38(6):486-7. PubMed ID: 19862708
[No Abstract] [Full Text] [Related]
23. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
Epstein JE; Charoenvit Y; Kester KE; Wang R; Newcomer R; Fitzpatrick S; Richie TL; Tornieporth N; Heppner DG; Ockenhouse C; Majam V; Holland C; Abot E; Ganeshan H; Berzins M; Jones T; Freydberg CN; Ng J; Norman J; Carucci DJ; Cohen J; Hoffman SL
Vaccine; 2004 Apr; 22(13-14):1592-603. PubMed ID: 15068840
[TBL] [Abstract][Full Text] [Related]
24. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.
Moorthy VS; Diggs C; Ferro S; Good MF; Herrera S; Hill AV; Imoukhuede EB; Kumar S; Loucq C; Marsh K; Ockenhouse CF; Richie TL; Sauerwein RW
Vaccine; 2009 Sep; 27(42):5719-25. PubMed ID: 19654061
[TBL] [Abstract][Full Text] [Related]
25. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites.
Bergmann ES; Ballou RW; Krzych U
Cell Immunol; 1997 Sep; 180(2):143-52. PubMed ID: 9341744
[TBL] [Abstract][Full Text] [Related]
26. An update on the search for a Plasmodium vivax vaccine.
Herrera S; Corradin G; Arévalo-Herrera M
Trends Parasitol; 2007 Mar; 23(3):122-8. PubMed ID: 17258937
[TBL] [Abstract][Full Text] [Related]
27. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
Breman JG; Alilio MS; Mills A
Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):1-15. PubMed ID: 15331814
[TBL] [Abstract][Full Text] [Related]
28. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.
Yadava A; Nurmukhambetova S; Pichugin AV; Lumsden JM
J Infect Dis; 2012 May; 205(9):1456-63. PubMed ID: 22457289
[TBL] [Abstract][Full Text] [Related]
29. Targeting Plasmodium liver stages: better late than never.
Borrmann S; Matuschewski K
Trends Mol Med; 2011 Sep; 17(9):527-36. PubMed ID: 21737347
[TBL] [Abstract][Full Text] [Related]
30. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
[TBL] [Abstract][Full Text] [Related]
32. The Promise of a Malaria Vaccine-Are We Closer?
Laurens MB
Annu Rev Microbiol; 2018 Sep; 72():273-292. PubMed ID: 30200856
[TBL] [Abstract][Full Text] [Related]
33. [Achievements and perspectives of research into development of a vaccine against malaria].
Wiśniewski M; Zak DJ
Wiad Parazytol; 2010; 56(2):133-40. PubMed ID: 20707297
[TBL] [Abstract][Full Text] [Related]
34. Malaria vaccine development: persistent challenges.
Vaughan AM; Kappe SH
Curr Opin Immunol; 2012 Jun; 24(3):324-31. PubMed ID: 22521906
[TBL] [Abstract][Full Text] [Related]
35. Vaccines against malaria-still a long way to go.
Matuschewski K
FEBS J; 2017 Aug; 284(16):2560-2568. PubMed ID: 28500775
[TBL] [Abstract][Full Text] [Related]
36. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines.
Penny MA; Maire N; Studer A; Schapira A; Smith TA
PLoS One; 2008 Sep; 3(9):e3193. PubMed ID: 18784833
[TBL] [Abstract][Full Text] [Related]
37. Malaria Vaccines: Progress to Date.
Stanisic DI; Good MF
BioDrugs; 2023 Nov; 37(6):737-756. PubMed ID: 37728713
[TBL] [Abstract][Full Text] [Related]
38. Recent developments in malaria vaccinology.
Halbroth BR; Draper SJ
Adv Parasitol; 2015 Apr; 88():1-49. PubMed ID: 25911364
[TBL] [Abstract][Full Text] [Related]
39. Identification of Novel Malaria Transmission-Blocking Vaccine Candidates.
Takashima E; Tachibana M; Morita M; Nagaoka H; Kanoi BN; Tsuboi T
Front Cell Infect Microbiol; 2021; 11():805482. PubMed ID: 34917521
[TBL] [Abstract][Full Text] [Related]
40. Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization.
Moncunill G; Scholzen A; Mpina M; Nhabomba A; Hounkpatin AB; Osaba L; Valls R; Campo JJ; Sanz H; Jairoce C; Williams NA; Pasini EM; Arteta D; Maynou J; Palacios L; Duran-Frigola M; Aponte JJ; Kocken CHM; Agnandji ST; Mas JM; Mordmüller B; Daubenberger C; Sauerwein R; Dobaño C
Sci Transl Med; 2020 May; 12(543):. PubMed ID: 32404508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
